Toxicological effects of atenolol and venlafaxine on zebrafish tissues: Bioaccumulation, DNA hypomethylation, and molecular mechanism

Lin, Wenting; Huang, Zixin; Ping, Senwen; Shuan, Zhang; Wen, Xiufang; He, Yuhe; Ren, Yuan

doi:10.1016/j.envpol.2022.118898

Cited by 15 publications

(7 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only a handful of studies have investigated the distribution of pharmaceuticals within the bodies of exposed wild fish , where drug accumulation is compound- and species-specific. , Instead, the majority of distribution data available for pharmaceuticals in fish are from time-course laboratory bioconcentration studies. In one such study, atenolol and venlafaxine displayed tissue-specific distribution in zebrafish, with bioaccumulation directly correlating with the lipid content of each tissue . Predictably, accumulation potential was shown to be governed by drug hydrophobicity, with venlafaxine (log K OW 3.28) accumulating to a greater extent than atenolol (log K OW 0.16) in the studied tissues.…”

Section: Susceptibility Of Fish To Human Apis In the Environment – In...mentioning

confidence: 99%

“…Predictably, accumulation potential was shown to be governed by drug hydrophobicity, with venlafaxine (log K OW 3.28) accumulating to a greater extent than atenolol (log K OW 0.16) in the studied tissues. Importantly, the molecules of both these APIs are small enough to cross the blood–brain barrier (MW < 400) and accumulate in the lipid-rich brain tissue as well. , Hydrophilic APIs may also exhibit tissue-specific toxicity, as seen for the nephrotoxic aminoglycosides (log K OW < −3), which accumulate in the kidneys . Like absorption (see Absorption), drug partitioning is influenced by transmembrane pH and electrical gradients, as well as membrane composition and active efflux processes. , …”

Section: Susceptibility Of Fish To Human Apis In the Environment – In...mentioning

confidence: 99%

See 1 more Smart Citation

Factors Determining the Susceptibility of Fish to Effects of Human Pharmaceuticals

Matthee

Brown

Lange

et al. 2023

Environ. Sci. Technol.

View full text Add to dashboard Cite

The increasing levels and frequencies at which active pharmaceutical ingredients (APIs) are being detected in the environment are of significant concern, especially considering the potential adverse effects they may have on nontarget species such as fish. With many pharmaceuticals lacking environmental risk assessments, there is a need to better define and understand the potential risks that APIs and their biotransformation products pose to fish, while still minimizing the use of experimental animals. There are both extrinsic (environmentand drug-related) and intrinsic (fish-related) factors that make fish potentially vulnerable to the effects of human drugs, but which are not necessarily captured in nonfish tests. This critical review explores these factors, particularly focusing on the distinctive physiological processes in fish that underlie drug absorption, distribution, metabolism, excretion and toxicity (ADMET). Focal points include the impact of fish life stage and species on drug absorption (A) via multiple routes; the potential implications of fish's unique blood pH and plasma composition on the distribution (D) of drug molecules throughout the body; how fish's endothermic nature and the varied expression and activity of drug-metabolizing enzymes in their tissues may affect drug metabolism (M); and how their distinctive physiologies may impact the relative contribution of different excretory organs to the excretion (E) of APIs and metabolites. These discussions give insight into where existing data on drug properties, pharmacokinetics and pharmacodynamics from mammalian and clinical studies may or may not help to inform on environmental risks of APIs in fish.

show abstract

Section: Susceptibility Of Fish To Human Apis In the Environment – In...mentioning

confidence: 99%

Section: Susceptibility Of Fish To Human Apis In the Environment – In...mentioning

confidence: 99%

Factors Determining the Susceptibility of Fish to Effects of Human Pharmaceuticals

Matthee

Brown

Lange

et al. 2023

Environ. Sci. Technol.

View full text Add to dashboard Cite

show abstract

“…Beta blockers are also observed to modulate epigenetic regulations. Recently, a study conducted in zebrafish demonstrated the ability of the beta blocker atenolol to reduce the methylation of DNA [163]. This was exhibited to be mediated by atenolol's binding and inhibition of DNMT1.…”

Section: Beta Blockersmentioning

confidence: 99%

Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?

Gladwell,

Ahiarah,

Rasheed

et al. 2023

Life

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of death worldwide. In addition to the high mortality rate, people suffering from CVD often endure difficulties with physical activities and productivity that significantly affect their quality of life. The high prevalence of debilitating risk factors such as obesity, type 2 diabetes mellitus, smoking, hypertension, and hyperlipidemia only predicts a bleak future. Current traditional CVD interventions offer temporary respite; however, they compound the severe economic strain of health-related expenditures. Furthermore, these therapeutics can be prescribed indefinitely. Recent advances in the field of epigenetics have generated new treatment options by confronting CVD at an epigenetic level. This involves modulating gene expression by altering the organization of our genome rather than altering the DNA sequence itself. Epigenetic changes are heritable, reversible, and influenced by environmental factors such as medications. As CVD is physiologically and pathologically diverse in nature, epigenetic interventions can offer a ray of hope to replace or be combined with traditional therapeutics to provide the prospect of addressing more than just the symptoms of CVD. This review discusses various risk factors contributing to CVD, perspectives of current traditional medications in practice, and a focus on potential epigenetic therapeutics to be used as alternatives.

show abstract

“…They are stable and water soluble because of the amide and hydroxyl groups in their chemical structure 17 . In the wastewater treatment facility (India), PCM has been found to range from 0.003 to 31 g L −1 , while ATL may reach 300 g L −1 18,19 . Drug pollution in water bodies is becoming a severe environmental issue, necessitating the removal of the pollutants in a timely, effective, energy‐saving, sustainable, and affordable manner 20–22 .…”

Section: Introductionmentioning

confidence: 99%

“…17 In the wastewater treatment facility (India), PCM has been found to range from 0.003 to 31 g L À1 , while ATL may reach 300 g L À1 . 18,19 Drug pollution in water bodies is becoming a severe environmental issue, necessitating the removal of the pollutants in a timely, effective, energy-saving, sustainable, and affordable manner. [20][21][22] To far, a variety of conventional approaches have been employed for the remediation of these medications, each of which has its own set of drawbacks, including high cost, poor yield, a wide temperature range, a high E-factor, and the development of harmful unwanted secondary pollutants.…”

mentioning

confidence: 99%

Efficient photocatalytic degradation of emerging pollutants by green synthesized Prussian blue analogue nanocomposite

Yadav

Rani

Shanker

2022

Env Prog and Sustain Energy

View full text Add to dashboard Cite

Worldwide consumption, toxicity, and bioaccumulation of paracetamol (PCM) and atenolol (ATL) has drawn attention of researchers over last decades. A small portion of these drugs is absorbed by human body and rest of them is excreted through urine and feces to the environment (water bodies and soil) which might result in negative impacts. Nanocomposite of chromium oxide coupled with zinc hexacyanocobaltates (Cr 2 O 3 @ZnHCC) was synthesized by a green-method using Sapindus mukorossi seed-extract for the removal of targeted drugs. Microscopic and spectroscopic analysis of Cr 2 O 3 @ZnHCC showed uniformly incorporated prisms into cubic structure having ~75 nm particle size. Well-characterized Cr 2 O 3 @ZnHCC and individuals (Cr 2 O 3 & ZnHCC) were utilized for the degradation of PCM and ATL under direct sunlight and dark conditions. Highest degradation of targeted drugs (91%-94%) resulted at 20 mg L À1 concentration of pollutant, 25 mg of catalyst dose, and pH ~7 under daylight exposure (5 h). First-order kinetics followed with a high adsorption capacity, X m (13.4-14.5 mg g À1 ) value was obtained to confirm the strong binding with the pollutants. Moreover, Cr 2 O 3 @ZnHCC substantially suppressed the half-life of targeted drugs (PCM: 0.6 h; ATL: 2.9 h) and converted them into safer-small metabolites as confirmed by liquid chromatography-mass-spectrometry analysis, and the reduction of carbon content was confirmed by total organic carbon analysis. The charge separation mechanism was assisted by UV reflectance and photoluminescence data. The synthesized green-nano photocatalyst displayed high reproducibility (up to 10th cycle), sensitivity, and stability during the degradation process which makes this a suitable candidate for industrial applications.

show abstract

Toxicological effects of atenolol and venlafaxine on zebrafish tissues: Bioaccumulation, DNA hypomethylation, and molecular mechanism

Cited by 15 publications

References 53 publications

Factors Determining the Susceptibility of Fish to Effects of Human Pharmaceuticals

Factors Determining the Susceptibility of Fish to Effects of Human Pharmaceuticals

Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?

Efficient photocatalytic degradation of emerging pollutants by green synthesized Prussian blue analogue nanocomposite

Contact Info

Product

Resources

About